CYCC Past Earnings image   This CYCC past earnings page last updated 11/10/2022
CYCC Past Earnings
PeriodPast Earnings DateGAAP
Q3 202211/9/2022-0.420
Q2 20228/10/2022-0.460
Q1 20225/11/2022-0.420
Q4 20213/28/2022-0.540
Q3 202111/10/2021-0.540
Q2 20218/11/2021-0.560
Q1 20215/12/2021-0.500
Q4 20202/25/2021-1.340
Q3 202011/11/2020-0.470
Q2 20208/12/2020-0.580
Q1 20205/12/2020-1.480
Q4 20192/26/2020-2.800
Q3 201911/13/2019-2.200
Q2 20198/13/2019-2.200
Q1 20195/14/2019-2.800
Q4 20183/27/2019-3.400
Q3 201811/12/2018-3.600
Q2 20188/9/2018-3.200
Q1 20185/14/2018-2.400
Q4 20173/28/20182.200
Q3 201711/9/2017-3.800
Q2 20178/9/2017-10.000
Q1 20175/11/2017-7.600
Q4 20163/28/2017-13.800
Q3 201611/14/2016-17.200
Q2 20168/10/2016-20.200
Q1 20165/11/2016-21.600
Q4 20153/24/2016-24.000
Q3 201511/12/2015-19.200
Q2 20158/11/2015-24.000
Q1 20155/12/2015-45.600
Q4 20143/24/2015-50.400
Q3 201411/11/2014-52.800
Q2 20148/12/2014-52.800
Q1 20145/13/2014-60.000
Q4 20133/25/2014-45.600
Q3 201311/12/2013-76.800
Q2 20138/14/201324.000
Q1 20135/13/2013-283.200
Q4 20123/27/2013-141.600
CYCC Past Revenue
PeriodPast Earnings DateGAAP
Q3 202211/9/2022NA
Q2 20228/10/2022NA
Q1 20225/11/2022NA
Q4 20213/28/2022NA
Q3 202111/10/2021NA
Q2 20218/11/2021NA
Q1 20215/12/2021NA
Q4 20202/25/2021NA
Q3 202011/11/2020NA
Q2 20208/12/2020NA
Q1 20205/12/2020NA
Q4 20192/26/2020NA
Q3 201911/13/2019NA
Q2 20198/13/2019NA
Q1 20195/14/2019NA
Q4 20183/27/2019150000
Q3 201811/12/2018NA
Q2 20188/9/2018NA
Q1 20185/14/2018NA
Q4 20173/28/2018NA
Q3 201711/9/2017NA
Q2 20178/9/2017NA
Q1 20175/11/2017NA
Q4 20163/28/2017277000
Q3 201611/14/2016205000
Q2 20168/10/2016222000
Q1 20165/11/2016139000
Q4 20153/24/2016424000
Q3 201511/12/2015715000
Q2 20158/11/2015296000
Q1 20155/12/2015512000
Q4 20143/24/2015247000
Q3 201411/11/2014735000
Q2 20148/12/2014264000
Q1 20145/13/2014396000
Q4 20133/25/2014299000
Q3 201311/12/201338000
Q2 20138/14/201326000
Q1 20135/13/2013NA
Q4 20123/27/2013NA
Quotes delayed 20 minutes

Email EnvelopeFree CYCC Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold S&P 500 Stocks
10 Most Overbought S&P 500 Stocks
10 ETFs With Stocks Insiders Are Buying
10 ETFs With Most Upside To Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active S&P Call & Put Options
Cyclacel Pharmaceuticals (CYCC) is categorized under the Healthcare sector; to help you further research past earnings across stocks, below are some other companies in the same sector:

CYCN Past Earnings
CYH Past Earnings
CYRX Past Earnings
CYT Past Earnings
CYTH Past Earnings
CYTK Past Earnings
DARE Past Earnings
DAWN Past Earnings
DBTX Past Earnings
DCPH Past Earnings

CYCC Past Earnings Q&A

What was the best and worst CYCC past earnings results?
For Cyclacel Pharmaceuticals, I'm wondering what the company's very best and worst earnings results have been, on an earnings per share basis?

✔️Accepted answer: The highest CYCC past earnings result in our data set was 24.000/share posted in Q2 2013, while the lowest was in Q1 2013 when CYCC posted -283.200/share.

  Suggested answer: The biggest top line earnings performance — aka revenue — quarter was in Q3 2014 when CYCC reported 735000 in revenue, while the quarter with the lowest revenue in our data set was Q3 2022 at NA of revenue.

  Suggested answer: There are 40 CYCC past earnings results in our data set.

On this page we presented the CYCC past earnings date information for Cyclacel Pharmaceuticals. Reviewing that CYCC Past Earnings for the company, we see that the highest past earnings result in our data set was in Q2 2013, when CYCC posted gaap of 24.000/share. Meanwhile the lowest CYCC past earnings result was in Q1 2013, when CYCC posted gaap of -283.200/share. Turning to top line revenue performance, the biggest revenue quarter in our data set was seen in Q3 2014 when CYCC reported 735000 in revenue, while the smallest revenue quarter was Q3 2022 when CYCC reported NA in revenue.

Any self directed investor doing their due diligence on CYCC or any other given stock can benefit from researching all of the Cyclacel Pharmaceuticals past earnings — and here, we present each quarter's result all together on one page for easy comparison. Studying this information can help when projecting future earnings, as well as determining whether the past earnings trajectory justifies the current stock value. That's why we bring you PastEarnings.com to make it easy for investors to investigate Cyclacel Pharmaceuticals past earnings, or the past earnings information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for CYCC. Thanks for visiting, and the next time you need to research CYCC past earnings or those of another stock, we hope you'll think of our site, as your go-to past earnings research resource of choice.

Recommended: CODA YTD Return, EQT Videos, KBE Options Chain.

 

CYCC Past Earnings | www.PastEarnings.com | Copyright © 2020 - 2022, All Rights Reserved

Nothing in PastEarnings.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.